My son pointed to a plastic army man on the ottoman. “That guy is a sniper,” he said. “He’s taking everyone out.” He placed a soldier on top of others on the living room floor. “This army is using dead bodies to build a wall. In war, you have to…
Whenever I’m out and about running errands, I’m aware of the possibility I’ll need to make a quick stop at, ahem, the public restroom. But though I have ALS and rely on a mobility scooter, it has never been a problem. That’s because I have a mental list of handicapped-accessible…
NPT520-34 is a new small molecule oral treatment being developed by Neuropore Therapies for potential use against neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. The therapy is believed to reduce neuroinflammation in the brain. What is ALS? ALS is a progressive disease…
Ultomiris (ravulizumab-cwvz) is an antibody-based medication that was being developed by Alexion Pharmaceuticals as a potential therapy for amyotrophic lateral sclerosis (ALS). However, after a Phase 3 clinical trial indicated that Ultomiris was not effective in treating ALS, Alexion in 2021 discontinued its development for the…
NT0502 is an experimental oral treatment being developed by Neos Therapeutics to reduce excessive salivation — drooling — a common problem in patients with amyotrophic lateral sclerosis (ALS). What is ALS? ALS is a neurological disease characterized by the progressive damage and loss of motor neurons, which are…
Dosing of healthy volunteers has been completed in a Phase 1 clinical trial evaluating Neos Therapeutics‘ experimental therapy NT0502 for chronic sialorrhea (excessive drooling), a common problem in people with amyotrophic lateral sclerosis (ALS). The open-label study includes 30 healthy adults who were assigned randomly to take one of…
Like many families, we played games over the holidays. Because my husband, Todd, is completely paralyzed due to ALS, we chose games in which he could participate. Apples to Apples worked well for him. I set his cards in the game’s box top, and he told me which card to…
For its promising investigational therapeutic approach to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics is the Buzz of BIO 2020 winner in the Public Therapeutic Biotech category. The Buzz of BIO contest identifies U.S. companies with groundbreaking, early-stage potential…
I tell potential customers that my Christmas wreaths will last until Easter. That usually gets a chuckle and often a sale. At a holiday craft fair, a gray-haired man topped my claim: “I bought one from you last year, and I just threw it out last week.” Longevity is an…
Mitsubishi Tanabe Pharma America (MTPA) and Soleo Health have entered into an agreement that will facilitate Soleo sharing real-world data about the use of MTPA’s Radicava (edaravone) in amyotrophic lateral sclerosis (ALS) patients. Radicava was approved for the treatment of ALS by the…
